key: cord-0920236-x5swm8o3
authors: Calleri, Alberto; Saracco, Margherita; Romagnoli, Renato; Martini, Silvia
title: Coronavirus disease 2019 vaccination in patients with cirrhosis: Does it work?
date: 2022-04-16
journal: Hepatol Commun
DOI: 10.1002/hep4.1931
sha: b30bc0880a4e504c02ac3be07d18ef5c52e8c489
doc_id: 920236
cord_uid: x5swm8o3

[Image: see text]

To the editor,

We read with interest the paper from Moon et al. [1] They reported a favorable outcome among patients with liver cirrhosis and coronavirus disease 2019 with at least one prior anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine dose. In their multicenter cohort, 21 patients with chronic liver disease (19 with cirrhosis) experienced COVID-19 after vaccination. Four of these patients required hospitalization after one Oxford-AstraZeneca dose (1 of them needed intensive care), and 3 patients were hospitalized after a median time of 3 weeks from two vaccine doses (2 patients received Oxford-AstraZeneca and 1 Pfizer-BioNTech); no deaths were reported. They also enrolled a group of 159 unvaccinated patients affected by cirrhosis and COVID-19; 74% of them required hospitalization and 9% died from COVID-19 lung disease. The authors did not report the immunoglobulin G (IgG) anti-SARS-CoV-2 after vaccination; however, they highlighted that antibody titers, along with T-cell responses, can predict protection against SARS-CoV-2. Therefore, we reported our experience with 89 patients before liver transplant (LT), 83% affected by cirrhosis. After a median time of 23 days from complete messenger RNA vaccination, 95% seroconverted with a median IgG value of 1980 binding antibody units (BAU)/mL, range 45-2080 (LIAISON SARS-CoV-2TrimericSIgGassay,positivevalue≥33.8 BAU/mL). [2] The titer decreased by 6-fold after 190 days; nevertheless, none of our patients with cirrhosis became IgG negative or developed COVID-19. Similarly, Thuluvath et al. [3] reported that only 4% of patients with cirrhosis had undetectable IgG anti-SARS-CoV-2 after vaccination, regardless of vaccine type. Finally, Ruether et al. [4] recently described a 98% anti-SARS-CoV-2 IgGpositive rate among 48 patients with cirrhosis and 100% in healthy subjects after two vaccine doses. Despite these reassuring data, neither paper reports the rate of infection after vaccination. [3, 4] These findings about the high rates of humoral response in patients with liver disease (Table 1) together with Moon's evidence of a favorable outcome of COVID-19 after full vaccination in patients with cirrhosis, strengthen the existing recommendations to have patients with cirrhosis vaccinated, especially in the pre-LT setting, considering the low humoral response achievable after transplant. The expected immune response fall after vaccination, as reported in healthy subjects and in our small cohort, might support the essential role of booster doses of the SARS-CoV-2 vaccine in patients with cirrhosis, as already reported in the post-LT setting. Turin Liver Transplant Center (Italy) and Ruether et al. [4] : DiaSorin LIAISON anti-SARS-CoV-2 TrimericS IgG immunoassay (cutoff 33.8 BAU/mL); Thuluvath et al., [3] Elecsys anti-SARS-CoV-2 semiquantitative assay (cutoff 0.4 U/mL). b EUROIMMUN SARS-CoV-2 interferon-γ release assay (cutoff 100 mUI/mL).

SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination

Seroconversion after coronavirus disease 2019 vaccination in patients awaiting liver transplantation: fact or fancy?

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases

SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients